AU2005232625B2 - Methods for controlling angiogenesis and cell proliferation - Google Patents

Methods for controlling angiogenesis and cell proliferation Download PDF

Info

Publication number
AU2005232625B2
AU2005232625B2 AU2005232625A AU2005232625A AU2005232625B2 AU 2005232625 B2 AU2005232625 B2 AU 2005232625B2 AU 2005232625 A AU2005232625 A AU 2005232625A AU 2005232625 A AU2005232625 A AU 2005232625A AU 2005232625 B2 AU2005232625 B2 AU 2005232625B2
Authority
AU
Australia
Prior art keywords
xaa
seq
cancer
glu
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005232625A
Other languages
English (en)
Other versions
AU2005232625A1 (en
Inventor
Cheng-Der Tony Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CANYON PHARMACEUTICALS GROUP AG
Original Assignee
CANYON PHARMACEUTICALS GROUP AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CANYON PHARMACEUTICALS GROUP AG filed Critical CANYON PHARMACEUTICALS GROUP AG
Publication of AU2005232625A1 publication Critical patent/AU2005232625A1/en
Application granted granted Critical
Publication of AU2005232625B2 publication Critical patent/AU2005232625B2/en
Assigned to CANYON PHARMACEUTICALS GROUP AG reassignment CANYON PHARMACEUTICALS GROUP AG Request for Assignment Assignors: CANYON PHARMACEUTICALS, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2005232625A 2004-04-12 2005-04-05 Methods for controlling angiogenesis and cell proliferation Ceased AU2005232625B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56174104P 2004-04-12 2004-04-12
US60/561,741 2004-04-12
PCT/US2005/011549 WO2005099749A2 (en) 2004-04-12 2005-04-05 Methods for controlling angiogenesis and cell proliferation

Publications (2)

Publication Number Publication Date
AU2005232625A1 AU2005232625A1 (en) 2005-10-27
AU2005232625B2 true AU2005232625B2 (en) 2011-07-28

Family

ID=35150501

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005232625A Ceased AU2005232625B2 (en) 2004-04-12 2005-04-05 Methods for controlling angiogenesis and cell proliferation

Country Status (13)

Country Link
US (3) US7795205B2 (cg-RX-API-DMAC7.html)
EP (1) EP1753291A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007532646A (cg-RX-API-DMAC7.html)
AU (1) AU2005232625B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0509876A (cg-RX-API-DMAC7.html)
CA (1) CA2562756C (cg-RX-API-DMAC7.html)
IL (1) IL178578A (cg-RX-API-DMAC7.html)
MY (1) MY146091A (cg-RX-API-DMAC7.html)
NZ (1) NZ551146A (cg-RX-API-DMAC7.html)
SG (1) SG160323A1 (cg-RX-API-DMAC7.html)
TW (1) TWI362941B (cg-RX-API-DMAC7.html)
WO (1) WO2005099749A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200609219B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
ATE480561T1 (de) 2004-10-19 2010-09-15 Lonza Ag Verfahren zur festphasen-peptidsynthese
US20100239651A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Nitrilopropionamide delivery systems
US20100239627A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Quarternary ammonium salts delivery systems
US20100239626A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Propanediol delivery systems
US20100239630A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Phosphonium salts delivery systems
US20100239650A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Isothiazolin biodelivery systems
US7803762B1 (en) 2009-08-20 2010-09-28 The Medicines Company Ready-to-use bivalirudin compositions
US7985733B1 (en) 2010-01-06 2011-07-26 The Medicines Company Buffer-based method for preparing bivalirudin drug product
US20230159629A1 (en) * 2011-01-13 2023-05-25 Case Western Reserve University Compositions and method of modulating growth factor function
CN104906037A (zh) * 2015-06-23 2015-09-16 广西复鑫益生物科技有限公司平南分公司 一种重组水蛭素滴眼液及其制备方法
CN110404060A (zh) * 2018-04-28 2019-11-05 复旦大学 凝血酶抑制剂在制备抗肿瘤侵袭转移药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0503829A2 (en) * 1991-03-08 1992-09-16 Ciba-Geigy Ag Hirudin for the inhibition of cancer metastasis

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
DE3586333T2 (de) 1984-03-27 1992-12-10 Transgene Sa Expressionsvektoren fuer hirudin, transformierte zellen und verfahren zur herstellung von hirudin.
DE3438296A1 (de) 1984-04-18 1985-11-07 Hoechst Ag, 6230 Frankfurt Neue polypeptide mit blutgerinnungshemmender wirkung, verfahren zu deren herstellung bzw. gewinnung, deren verwendung und diese enthaltende mittel
DE3583361D1 (de) 1984-06-14 1991-08-08 Ucp Gen Pharma Ag Verfahren zur herstellung von thrombin-inhibitoren.
DE3445532A1 (de) 1984-12-13 1986-06-19 Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn Hirudin-pa, desulfatohirudine-pa, verfahren zur herstellung und pharmazeutische mittel, die diese wirkstoffe enthalten
HU192646B (en) 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
ZA86746B (en) 1985-02-04 1986-09-24 Merrell Dow Pharma Novel peptidase inhibitors
DE3738541A1 (de) 1987-11-13 1989-05-24 Hoechst Ag Verfahren zur isolierung und reinigung von hirudin
FR2593518B1 (fr) 1985-05-02 1989-09-08 Transgene Sa Vecteurs d'expression et de secretion de l'hirudine par les levures transformees
MY101203A (en) 1985-12-12 1991-08-17 Ucp Gen Pharma Ag Production of thrombin iinhibitors.
MC1834A1 (fr) 1986-07-10 1988-06-03 Transgene Sa Bloc fonctionnel d'adn et plasmide codant pour l'hirudine,levure transformee,procede de preparation de l'hirudine,hirudine obtenue et son utilisation
US5352664A (en) 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
AU604925B2 (en) 1988-02-23 1991-01-03 Schering Aktiengesellschaft A hirudin derivative
AU614121B2 (en) 1988-05-04 1991-08-22 Novartis Ag Improvements in the production of polypeptides
GB8817160D0 (en) 1988-07-19 1988-08-24 Ciba Geigy Ag Novel proteins
GB8817161D0 (en) 1988-07-19 1988-08-24 Ciba Geigy Ag Modified proteins
EP0362002B1 (en) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV protease inhibitors
JPH04500802A (ja) * 1988-09-29 1992-02-13 バイオジェン インコーポレイテッド ヒルジンペプチド
ZA897514B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
FR2645175B1 (fr) 1989-03-31 1994-02-18 Transgene Sa Souche de saccharomyces cerevisiaeproductrice d'une proteine heterologue et procede de preparation de ladite proteine heterologue par fermentation de ladite souche
US5096092A (en) * 1990-03-13 1992-03-17 Mmm, Ltd. Food dispensing apparatus utilizing inflatable bladder
TW201303B (cg-RX-API-DMAC7.html) 1990-07-05 1993-03-01 Hoffmann La Roche
DE69130872T2 (de) 1990-11-08 1999-08-26 Japan Energy Corp. Sekretionsvektor, diesen enthaltene transformierte Mikroorganismen und Herstellung von Produkten durch obigen Mikroorganismus
DE4041185A1 (de) * 1990-12-21 1992-06-25 Knoll Ag Verwendung von hirudin und dessen muteinen zur kombinationsbehandlung von tumoren
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
CZ333492A3 (en) 1991-11-12 1993-09-15 Lilly Co Eli Dipeptide of l-azetidine-2-carboxylic acids and l-argininaldehyde, process of its preparation and pharmaceutical preparation in which said dipeptide is comprised
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
AU663169B2 (en) 1992-03-04 1995-09-28 Gyogyszerkutato Intezet Kft New anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for the preparation thereof
TW223629B (cg-RX-API-DMAC7.html) 1992-03-06 1994-05-11 Hoffmann La Roche
DE69329540T2 (de) 1992-09-04 2001-06-07 Novartis Ag, Basel Verfahren zur Herstellung von Proteaseinhibitoren
AU675981B2 (en) 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
GB9303275D0 (en) 1993-02-18 1993-04-07 Ciba Geigy Ag Pharmaceutical compositions
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
DE4321444A1 (de) 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
EP0648780A1 (en) 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
GB9401448D0 (en) 1994-01-26 1994-03-23 Ciba Geigy Ag Stable dry powders
GB9401447D0 (en) 1994-01-26 1994-03-23 Ciba Geigy Ag Pharmaceutical compositions
AU1025795A (en) 1994-01-27 1995-08-03 Mitsubishi Chemical Corporation Prolineamide derivatives
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5843925A (en) 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
FI973360L (fi) 1995-02-17 1997-08-15 Basf Ag Uusia dipeptidisiä amidiineja trombiininestäjiksi
SE9600216D0 (sv) 1996-01-18 1996-01-18 Hans Arne Hansson Styrning av läkningsprocesser
CA2253608A1 (en) 1996-05-01 1997-11-06 Louis Vignati Therapeutic treatment for vegf related diseases
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
DE10033195A1 (de) 2000-07-07 2002-03-21 Aventis Pharma Gmbh Bifunktionale Fusionsproteine aus Hirudin und TAP
WO2002028387A1 (en) 2000-10-03 2002-04-11 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0503829A2 (en) * 1991-03-08 1992-09-16 Ciba-Geigy Ag Hirudin for the inhibition of cancer metastasis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Esumi, N. et al. "Inhibition of Murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor." Cancer Research, 01 September 1991. vol 51, pages 4549-4556. *

Also Published As

Publication number Publication date
WO2005099749A2 (en) 2005-10-27
NZ551146A (en) 2009-04-30
ZA200609219B (en) 2012-02-29
IL178578A0 (en) 2007-02-11
JP2007532646A (ja) 2007-11-15
IL178578A (en) 2013-06-27
SG160323A1 (en) 2010-04-29
BRPI0509876A (pt) 2007-10-16
MY146091A (en) 2012-06-29
CA2562756C (en) 2011-08-23
AU2005232625A1 (en) 2005-10-27
WO2005099749A3 (en) 2006-08-03
US20110224150A1 (en) 2011-09-15
TW200538466A (en) 2005-12-01
TWI362941B (en) 2012-05-01
US20090269422A1 (en) 2009-10-29
US20050233966A1 (en) 2005-10-20
US7795205B2 (en) 2010-09-14
CA2562756A1 (en) 2005-10-27
EP1753291A4 (en) 2009-08-12
EP1753291A2 (en) 2007-02-21

Similar Documents

Publication Publication Date Title
US20110224150A1 (en) Methods for effecting regression of tumor mass and size in a metastasized tumor
US7820626B2 (en) Compositions and methods for treating diseases
CA2122519C (en) Cancer treatment and metastasis prevention
CN104800858B (zh) Hsp90抑制肽偶联物及其在肿瘤治疗中的应用
JPH10504828A (ja) 細胞活性調整のためのヒアルロン酸およびその誘導体
EP1496909B1 (en) Combination therapy for the treatment of cancer
CA2709027A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
AU2008338594A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (HSAA)
WO2002085117A1 (en) Methods and compositions for preventing and treating septic shock and endotoxemia
KR102008826B1 (ko) 나토키나제와 항염증제를 유효성분으로 포함하는 혈소판 응집 억제용 또는 혈전용해용 의약 조성물
CN114423461B (zh) 组合
JPH11246433A (ja) 心筋梗塞治療剤
JP6038795B2 (ja) ナトリウム利尿ペプチド受容体ｇｃ−ａアゴニスト及びｇｃ−ｂアゴニストを組み合わせてなる悪性腫瘍の増悪防止用医薬
EP3787661B1 (en) Combination of temozolomide and a par-1 conjugate for treating glioblastoma
WO2023026247A1 (en) Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea
JP2009046450A (ja) 抗がん剤へのヒアルロン酸添加
Rowinsky et al. Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer
KR20240041399A (ko) 항암 활성을 갖는 신규한 펩타이드 및 이의 용도
JP2875541B2 (ja) 血行再建術後の再閉塞防止剤
JP2006089455A (ja) 動脈瘤予防および／または治療剤
KR20100016392A (ko) 암의 치료에 기여하는 조성물 및 방법
HK1071310B (en) Combination therapy for the treatment of cancer

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CANYON PHARMACEUTICALS GROUP AG

Free format text: FORMER APPLICANT(S): CANYON PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired